About Concur Pharmaceuticals Private Limited
Data last updated: 17 December 2025
Concur Pharmaceuticals Private Limited is a private limited company based in Delhi, Delhi, India. It specialises in pharmaceutical retail and distribution, a part of the broader pharmaceuticals sector. Incorporated on 14 March 2011, the company has been in operation for over 15 years.
Registered with ROC Delhi under CIN U24100DL2011PTC215797.
Capital: an authorised share capital of ₹10 Lakh and a paid-up capital of ₹10 Lakh. It is led by directors including Amrit Kaushal and Patanjali Kumar.
Last AGM: 30 September 2024. Financial statements filed for year ended 31 March 2024. Office: Office Space No F7&F8 1St Floor St.Soldier Tower Plot No. 3&4 Community Center G Block, Vikaspuri, Delhi, Delhi, India – 110018.
As per the financials filed for FY 2024, the company reported a revenue of ₹9.98 Cr, a growth of 17% compared to the previous year.
The company has a workforce of approximately 61 employees as per the latest available data.
The company is associated with 1 brand - Concur Lives.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website concurlives.com.
-
Email*****@*****.com
-
Telephone+91-****-******
-
Website
-
Social Media**************
-
Registered AddressOffice Space No F7&F8 1St Floor St.Soldier Tower Plot No. 3&4 Community Center G Block, Vikaspuri, Delhi, Delhi, India – 110018
-
IndustryPharma, Pharmaceutical Retailers & Distributors
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
Associated Brands with Concur Pharmaceuticals Private Limited
Concur Pharmaceuticals Private Limited operates one associated brand: Concur Lives. These brands represent Concur Pharmaceuticals Private Limited's diversified market presence and brand portfolio.
| Brand | Description | Website |
|---|---|---|
| Offers pharmaceutical solutions for chronic diseases in India and globally. | concurlives.com |
Competitors & Alternatives of Concur Pharmaceuticals Private Limited
Brands and companies operating in the same space as Concur Pharmaceuticals Private Limited include Merck, Roivant Sciences, AbbVie and 7 more.
| Competitor | Description | Location | Founded |
|---|---|---|---|
Merck
|
Pharmaceutical products are manufactured and marketed worldwide. | Kenilworth, United Kingdom, United Kingdom | 1891 |
Roivant Sciences
|
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed. | New York, United States, United States | 2014 |
AbbVie
|
Biopharmaceutical research and drug development are conducted globally by AbbVie. | Chicago, United States, United States | 2012 |
Lilly
|
Traditional pharmaceutical medicines are developed for multiple health fields. | United States | 1876 |
Gilead
|
Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others | Foster City, United States, United States | 1987 |
United Therapeutics
|
Treatments for chronic and life-threatening diseases are developed and commercialized. | Silver Spring, United States, United States | 1998 |
Roche
|
Pharmaceuticals and diagnostics kits are developed for various diseases. | Basel, Switzerland, Switzerland | 1896 |
MorphoSys
|
Therapeutic antibodies for cancer and other diseases are developed. | Planegg, Germany, Germany | 1992 |
Eisai
|
Drugs for oncology and neurological disorders are developed by Eisai. | Tokyo, Japan, Japan | 1941 |
Vertex Pharmaceuticals
|
Developer of drugs for the treatment of multiple disorders | United States | 1989 |
Business Activity of Concur Pharmaceuticals Private Limited
Concur Pharmaceuticals Private Limited is engaged in the principal business activity of trade, with detailed activities including wholesale trading.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| G | Trade | G1 | Wholesale Trading | ********* |
Auditor Details of Concur Pharmaceuticals Private Limited
Concur Pharmaceuticals Private Limited is audited by Gupta Meenu & Associates for the financial year 2023. The auditor plays a crucial role in ensuring financial transparency and compliance with accounting standards.
| Name | Status | Appointment Date | Cessation Date |
|---|---|---|---|
| Gupta Meenu & Associates | blur-value | blur-value | blur-value |
Board of Directors of Concur Pharmaceuticals Private Limited
Concur Pharmaceuticals Private Limited is currently managed by 5 directors, with 5 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
|
Amrit Kaushal
Also directs:
Daikon Pharmaceuticals Private Limited
|
Director | 16 Jan 2012 | 14 Years 5 Months | Current |
|
Patanjali Kumar
Also directs:
Reggel Lifesciences Private Limited
|
Director | 16 Jan 2012 | 14 Years 5 Months | Current |
| Ajeet Kumar | Director | 14 Mar 2011 | 15 Years 3 Months | Current |
|
Sandip Hazari
Also directs:
Alegria Labs Private Limited, Shatnirvana Life Care Foundation
|
Director | 05 Mar 2012 | 14 Years 4 Months | Current |
| Ravi Shankar Choudhary | Director | 05 Mar 2012 | 14 Years 4 Months | Current |
Financials of Concur Pharmaceuticals Private Limited FY 2024 filings available
Concur Pharmaceuticals Private Limited reported revenue of ₹9.98 Cr (up 17% YoY) for FY 2024. Profit growth despite declining revenue indicates effective cost management and margin discipline.
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue from Operations | ***** | ***** | ***** | ***** | ***** |
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Other Income | ***** | ***** | ***** | ***** | ***** |
| Total Revenue | ***** | ***** | ***** | ***** | ***** |
| Expenses | |||||
| Total Expenses | ***** | ***** | ***** | ***** | ***** |
| Raw Material Cost | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory FG | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory WIP | ***** | ***** | ***** | ***** | ***** |
| Purchase of Traded Goods | ***** | ***** | ***** | ***** | ***** |
| Employee Cost | ***** | ***** | ***** | ***** | ***** |
| Managerial Remuneration | ***** | ***** | ***** | ***** | ***** |
| Audit Fees | ***** | ***** | ***** | ***** | ***** |
| Insurance | ***** | ***** | ***** | ***** | ***** |
| Power & Fuel | ***** | ***** | ***** | ***** | ***** |
| Interest | ***** | ***** | ***** | ***** | ***** |
| Depreciation | ***** | ***** | ***** | ***** | ***** |
| Other Expenses | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| EBITDA (Operating Profit) | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| Exceptional Items | ***** | ***** | ***** | ***** | ***** |
| Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Exceptional & Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Tax & Net Profit | |||||
| Tax Expense | ***** | ***** | ***** | ***** | ***** |
| Current Tax | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax | ***** | ***** | ***** | ***** | ***** |
| Profit from Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Tax on Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Profit | ***** | ***** | ***** | ***** | ***** |
| Net Margin % | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Shareholders' Funds | |||||
| Total Shareholders' Funds | ***** | ***** | ***** | ***** | ***** |
| Equity Capital | ***** | ***** | ***** | ***** | ***** |
| Reserves & Surplus | ***** | ***** | ***** | ***** | ***** |
| Money Against Warrants | ***** | ***** | ***** | ***** | ***** |
| Other Equity | ***** | ***** | ***** | ***** | ***** |
| Non-Current Liabilities | |||||
| Total Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Liabilities | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Current Liabilities | |||||
| Total Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Trade Payables | ***** | ***** | ***** | ***** | ***** |
| Other Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Total Equity & Liabilities | ***** | ***** | ***** | ***** | ***** |
| Non-Current Assets | |||||
| Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Tangible Assets | ***** | ***** | ***** | ***** | ***** |
| Intangible Assets | ***** | ***** | ***** | ***** | ***** |
| Capital WIP | ***** | ***** | ***** | ***** | ***** |
| Intangibles Under Dev | ***** | ***** | ***** | ***** | ***** |
| Investments | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Assets | ***** | ***** | ***** | ***** | ***** |
| LT Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Assets | |||||
| Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Investments | ***** | ***** | ***** | ***** | ***** |
| Inventories | ***** | ***** | ***** | ***** | ***** |
| Trade Receivables | ***** | ***** | ***** | ***** | ***** |
| Cash & Bank Balance | ***** | ***** | ***** | ***** | ***** |
| ST Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Current Assets | ***** | ***** | ***** | ***** | ***** |
| Total Assets | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Cash from Operating Activities (CFO) | |||||
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Non-Cash Adjustments | ***** | ***** | ***** | ***** | ***** |
| + Interest Expense | ***** | ***** | ***** | ***** | ***** |
| + Depreciation | ***** | ***** | ***** | ***** | ***** |
| +/- Unrealized Forex | ***** | ***** | ***** | ***** | ***** |
| - Dividend Income | ***** | ***** | ***** | ***** | ***** |
| - Interest Income | ***** | ***** | ***** | ***** | ***** |
| +/- Other Non-Cash Items | ***** | ***** | ***** | ***** | ***** |
| Changes in Working Capital | ***** | ***** | ***** | ***** | ***** |
| +/- Inventory | ***** | ***** | ***** | ***** | ***** |
| +/- Debtors | ***** | ***** | ***** | ***** | ***** |
| +/- Creditors | ***** | ***** | ***** | ***** | ***** |
| Reconciliation Adjustments | ***** | ***** | ***** | ***** | ***** |
| Cash Generated from Operations | ***** | ***** | ***** | ***** | ***** |
| Income Taxes Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFO (Cash from Operations) | ***** | ***** | ***** | ***** | ***** |
| Cash from Investing Activities (CFI) | |||||
| Acquisitions & Disposals | ***** | ***** | ***** | ***** | ***** |
| Disposal of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Acquisition of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Capex | ***** | ***** | ***** | ***** | ***** |
| Purchase of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Sale of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Other Investing Cash Flows | ***** | ***** | ***** | ***** | ***** |
| Net CFI (Cash from Investing) | ***** | ***** | ***** | ***** | ***** |
| Cash from Financing Activities (CFF) | |||||
| Equity Issuance | ***** | ***** | ***** | ***** | ***** |
| Debt Raised | ***** | ***** | ***** | ***** | ***** |
| Debt Repaid | ***** | ***** | ***** | ***** | ***** |
| Dividends Paid | ***** | ***** | ***** | ***** | ***** |
| Interest Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFF (Cash from Financing) | ***** | ***** | ***** | ***** | ***** |
| Net Cash Position | |||||
| Net Change in Cash (Pre-Forex) | ***** | ***** | ***** | ***** | ***** |
| Closing Cash & Equivalents | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Liquidity | |||||
| Current Ratio | ***** | ***** | ***** | ***** | ***** |
| Quick Ratio | ***** | ***** | ***** | ***** | ***** |
| Cash Ratio | ***** | ***** | ***** | ***** | ***** |
| Efficiency | |||||
| Inventory Days | ***** | ***** | ***** | ***** | ***** |
| Debtor Days | ***** | ***** | ***** | ***** | ***** |
| Creditor Days | ***** | ***** | ***** | ***** | ***** |
| Cash Conversion Cycle | ***** | ***** | ***** | ***** | ***** |
| Asset Turnover | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| Net Profit Margin % | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| ROE % | ***** | ***** | ***** | ***** | ***** |
| ROCE % | ***** | ***** | ***** | ***** | ***** |
| Net Worth Margin % | ***** | ***** | ***** | ***** | ***** |
| Growth | |||||
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Leverage | |||||
| Equity Multiplier | ***** | ***** | ***** | ***** | ***** |
| Debt / EBITDA | ***** | ***** | ***** | ***** | ***** |
| Solvency | |||||
| D/E Ratio | ***** | ***** | ***** | ***** | ***** |
| ICR | ***** | ***** | ***** | ***** | ***** |
Consolidated Statements
Income Statement, Balance Sheet, Cash Flow & Ratios available in the full report.
Shareholding Pattern of Concur Pharmaceuticals Private Limited
As of FY 2023, Concur Pharmaceuticals Private Limited's shareholding pattern shows 23.21% by promoters.
| Year | 2025 |
|---|---|
| Promoters | 33.19% |
| DII | 23.22% |
| FII | 18.28% |
| Public | 22.89% |
| Others | 2.42% |
Charges & Borrowings Concur Pharmaceuticals Private Limited
Concur Pharmaceuticals Private Limited does not have any charges (loans) registered with the Registrar of Companies.
Employees and EPFO Compliance at Concur Pharmaceuticals Private Limited
Concur Pharmaceuticals Private Limited has a workforce of 61 employees as of Apr 10, 2024.
Employee Count & EPFO Data of Concur Pharmaceuticals Private Limited
Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.
GST Compliance of Concur Pharmaceuticals Private Limited
GSTIN & GST Filing Data of Concur Pharmaceuticals Private Limited
Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.
Credit Ratings, Litigation & Regulatory Alerts for Concur Pharmaceuticals Private Limited
Credit Ratings, Legal Cases & Regulatory Alerts of Concur Pharmaceuticals Private Limited
Access complete credit rating history, litigation records, regulatory alerts, and compliance data.
MSME Payment Delays by Concur Pharmaceuticals Private Limited
MSME Payment Delays by Concur Pharmaceuticals Private Limited
Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.
Subsidiaries & Group Companies of Concur Pharmaceuticals Private Limited
Subsidiaries & Group Companies of Concur Pharmaceuticals Private Limited
See the full corporate group - holding company, subsidiaries, associates and joint ventures of Concur Pharmaceuticals Private Limited with ownership details.
MCA Filings & Documents of Concur Pharmaceuticals Private Limited
MCA Filings & Documents of Concur Pharmaceuticals Private Limited
Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.
Recent Activity on Concur Pharmaceuticals Private Limited
Frequently Asked Questions about Concur Pharmaceuticals Private Limited
Concur Pharmaceuticals Private Limited is an active private limited company in the pharma sector based in Delhi, Delhi, India. It was incorporated on 14 March 2011 (15+ years old) and is registered under CIN U24100DL2011PTC215797. The company has 61 employees.
Concur Pharmaceuticals Private Limited reported revenue of ₹9.98 Cr for FY 2024 (up 17.00% YoY).
The current directors of Concur Pharmaceuticals Private Limited are:
The primary industry of Concur Pharmaceuticals Private Limited is pharma. The company specifically operates in pharmaceutical retailers and distributors. The company is currently active in this sector.
Concur Pharmaceuticals Private Limited can be reached at the registered office: Office Space No F7&F8 1St Floor St.Soldier Tower Plot No. 3&4 Community Center G Block, Vikaspuri, Delhi, Delhi, India – 110018, or through the website concurlives.com.
The authorised capital is ₹10 Lakh, and the paid-up capital is ₹10 Lakh.